


Synthesis of Diverse Lactam Carboxamides Leading to the Discovery of a New Transcription-Factor Inhibitor**

Pui Yee Ng, Yuchen Tang, Wendy M. Knosp, H. Scott Stadler,* and Jared T. Shaw*

The selective induction or disruption of protein–biopolymer interactions with small molecules is important for the chemical control of molecular pathways fundamental to cell and disease biology.^[1,2] However, the structural requirements for compounds that selectively disrupt protein–protein and protein–DNA interactions are largely unknown.^[3] The challenge of discovering selective modulators of protein–biopolymer interactions rests on the synthesis of compounds with sufficient complexity to interact with an appropriate interface site on a target protein. To address this challenge, we are developing new strategies for the efficient synthesis of complex libraries of small molecules for use in high-throughput screening experiments when the structural requirements for activity are not previously known.^[4] Herein we describe how the synthesis and screening of a library of lactam carboxamides revealed a new inhibitor of HOXA13, a transcription factor that regulates mammalian development^[5] and certain kinds of cancer.^[6]


The formal cycloaddition between imines and anhydrides is an ideal starting point for the synthesis of small molecules with varied core structures that incorporate elements of functional group, skeletal, and stereochemical diversity (Scheme 1). Common imine **5** provides access to distinct



Scheme 1. Incorporation of elements of functional-group, skeletal, and stereochemical diversity.

carboxy- γ -lactam and carboxy-2-quinolone structures, thus forming the basis for an efficient compound library synthesis. As a starting point, we have recently disclosed stereoselective methods for the synthesis of carboxy γ -lactams related to **1a** and **2a**, which provide distinct products based on the incorporation of either the aryl (**6**) or thioaryl (**7**) succinic anhydrides (Scheme 2).^[7–8]

4-Carboxy-2-quinolones in the *syn* (**3**) and *anti* (**4**) forms, which feature complementary skeletons when compared with



Scheme 2. Conditions: a) **5a** or **b** + **6**, toluene, 110°C; b) **5a** or **c** + **7**, toluene, 110°C, c) BnNH_2 , HATU. Minimized (MM2) structures of **1a** and **2a**, N-CH_3 groups depicted for clarity. Yields based on isolation of final product after three steps. Yields of **1a** and **1b** include preparation of anhydride **6**. HATU = *O*-(7-Azabenzotriazol-1-yl)-*N,N,N',N'*-tetra-methyluronium hexafluorophosphate.

[*] Dr. P. Y. Ng, Dr. Y. Tang, Dr. J. T. Shaw^[4]
The Broad Institute of Harvard and MIT
7 Cambridge Center, Cambridge, MA 02142 (USA)
Fax: (+1) 617-324-4399
E-mail: shaw@chem.ucdavis.edu

Prof. H. S. Stadler
Department of Molecular and Medical Genetics
Oregon Health and Science University
3181 SW Sam Jackson Park Rd, Portland, OR 97239 (USA)
Fax: (+1) 503-494-34000
E-mail: hss@shcc.org


Dr. W. M. Knosp
Department of Anatomy
University of California San Francisco
San Francisco, CA 94158-232 (USA)

[†] Current address:
Department of Chemistry
University of California, Davis
One Shields Ave, Davis, CA 95616 (USA)

[**] This work was conducted under the aegis of the Broad Institute Center for Methodology and Library Development (CMLD, NIGMS P50 GM069721). The HOXA13 small molecule screen was supported by a grant from the Shriners Hospital for Children (H.S.S.). The project has been funded in part with Federal funds from the NCI's Initiative for Chemical Genetics, NIH under Contract No. N01-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Service, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The authors thank Prof. Stuart Schreiber (Harvard University, Broad Institute, and Howard Hughes Medical Institute) for insightful discussions.

Supporting information for this article is available on the WWW under <http://www.angewandte.org> or from the author.

carboxy- γ -lactams **1** and **2**, were also formed from imine **5** (Scheme 3). This reaction was first reported by Cushman et al.,^[9] who has subsequently employed this transformation in a



Scheme 3. Conditions: a) **5a** or **b** + **8**, CH₂Cl₂, 23 °C; b) **5b** or **c** + **9**, benzene, 23 °C, c) (p-CH₃OC₆H₅)CH₂CH₂NH₂, HATU. Minimized (MM2) structures of des-iodo-**3b** and **5**, N-CH₃ groups depicted for clarity.


variety of syntheses.^[10] Although the initial reaction of anhydride **8** with imines **5a** and **5b** provides the *cis* cycloadducts, complete epimerization to the *trans* isomer is observed during conversion to amide **3a** and **3b**. Anhydride **9** also forms the *cis*-isoquinolone, but in this case epimerization during amide formation is prevented by the presence of the quaternary stereogenic center. Although these compounds only differ by a single methyl substituent, the different stereochemical array (*syn* versus *anti*) has a profound impact on the orientation of the two substituents.

The pathways described for the synthesis of lactams **1–4** were developed to prepare a structurally diverse library of 400 discrete compounds on a solid phase by using split-pool techniques.^[11] As a wide array of imines are available for the stereoselective cycloaddition reactions with anhydrides **6–9**, diverse amine reagents were selected for each anhydride based on optimal conversion and diastereoselectivity (Scheme 4). Arylsuccinic anhydride **6** reacted with high (>90:10) diastereoselectivity to afford the γ -lactam products. Anhydrides **7** and **8** exhibited greater reactivity and improved substrate tolerance to react with a wider variety of imines with excellent (>95:5) diastereoselectivity. The cycloaddition

reaction of 4-methylhomophthalic anhydride (**9**) was included to increase stereochemical diversity, in which the incorporation of the 4-methyl substituent prevents isomerization and provides the *cis*-fused product with good diastereoselectivity (80:20–93:7). Primary-amine (R²NH₂) building blocks with lower than average molecular weights were chosen for the final amide-formation reaction owing to their high reactivity and incorporation of additional hydrogen-bonding capabilities.

This diverse library is useful for the study of biological process by using phenotypic readouts in whole cells and multicellular organisms when the structural requirements for activity are not known or when a pathway with multiple potential targets is examined. In addition, the structural requirements for compounds that selectively disrupt protein–protein and protein–DNA interactions, which can be studied biochemically, are still emerging. This collection of compounds has been included in over 150 high-throughput screens, of which the majority involved phenotypic readouts or the detection of protein–biopolymer interactions.^[12] Although we sought to explore a broad range of biological processes that will contribute to global analyses and activity profiling,^[13] this study describes our efforts to investigate the small-molecule control of gene expression by inhibiting transcription-factor–DNA binding.

A high-throughput screen by using fluorescence polarization^[14] revealed lactam carboxamides **30** and **31** that inhibit the interaction of the HOXA13 DNA binding domain to its target DNA sequence (Figure 1).^[15] HOXA13 is a member of the conserved Hox transcription-factor family whose function is required for the normal development of the limb and genitourinary tissues.^[16] Recognizing that tumor formation closely mimics the developmental processes controlled by Hox proteins and that Hox proteins are often aberrantly expressed in cancerous tissues, strategies to disrupt Hox protein–DNA interactions could prove useful in the treatment of the disease state.^[17] The known DNA intercalator 9-hydroxyelipticine^[18] and other planar compounds suspected of interacting unselectively with the DNA oligonucleotide were also identified. The concentration-dependent activity of **31** was confirmed and an IC₅₀ value of 6.5 μ M was determined.^[19] No disruption of the control Trp-repressor–DNA



Scheme 4. Synthesis of 400 diverse lactams from the reactions of solid-phase imines with anhydrides **6–9** followed by amide formation.




Figure 1. A) High-throughput screen for small molecules that disrupt a transcription factor–DNA complex. B) Primary-screening hits. C) Concentration-dependence of the activity of **31** against HOXA13–DNA and Trp repressor–DNA complexes.

complex was observed, indicating that **31** specifically interferes with HOXA13 DNA binding and does not unselectively bind to DNA.

The activity of **31** in cells was confirmed by using a reporter gene assay in which the expression of luciferase is under the control of HOXA13. Addition of compound **31** had little effect on the expression of luciferase (Figure 2, col-




Figure 2. Inhibition of HOXA13 in NG108-15 cells. Addition of **31** reverses the ability of HOXA13 to repress expression of luciferase.

umns 1 and 2). In the presence of HOXA13, luciferase activity is suppressed by roughly 80%. Adding compound **31** produced a concentration-dependent increase in luciferase activity, indicating that repression by HOXA13 was effectively inhibited in cells.

Our discovery of a new transcription-factor inhibitor from this library of lactam carboxamides affirms the idea that structurally diverse compounds are useful starting points in the search for chemical modulators of protein–biopolymer interactions. Given the difficulty in selectively targeting transcription factors,^[3,20–22] the activity of **31** is a significant advance in the chemical control of transcription. We are currently establishing the structure–activity relationships of

this compound in preparation for future studies in vivo. A full account of the synthesis, computational analysis of diversity, and biological profiling will be disclosed shortly.

Received: February 20, 2007

Revised: March 20, 2007

Published online: June 14, 2007

Keywords: combinatorial chemistry · DNA · gene expression · lactams · proteins

- [1] For recent reviews on small-molecule modulation of biological processes, see: a) S. L. Schreiber, *Nat. Chem. Biol.* **2005**, *1*, 64–66; b) P. Arya, R. Joseph, Z. Gan, B. Rakic, *Chem. Biol.* **2005**, *12*, 163–180; c) D. R. Spring, *Chem. Soc. Rev.* **2005**, *34*, 472–482; d) N. Tolliday, P. A. Clemons, P. Ferraiolo, A. N. Koehler, T. A. Lewis, X. Li, S. L. Schreiber, D. S. Gerhard, S. Eliasof, *Cancer Res.* **2006**, *66*, 8935–8942; e) D. S. Tan, *Nat. Chem. Biol.* **2005**, *1*, 74–84.
- [2] For recent reviews on small-molecule disruption of protein–protein interactions, see: a) H. Yin, A. D. Hamilton, *Angew. Chem.* **2005**, *117*, 4200–4235; *Angew. Chem. Int. Ed.* **2005**, *44*, 4130–4163; b) M. R. Arkin, J. A. Wells, *Nat. Rev. Drug Discovery* **2004**, *3*, 301–317; c) T. Berg, *Angew. Chem.* **2003**, *115*, 2566–2586; *Angew. Chem. Int. Ed.* **2003**, *42*, 2462–2481; ; d) D. L. Boger, J. Desharnais, K. Capps, *Angew. Chem.* **2003**, *115*, 4270–4309; *Angew. Chem. Int. Ed.* **2003**, *42*, 4138–4176.
- [3] For recent reviews on small-molecule modulation of transcription factors, see: a) H.-D. Arndt, *Angew. Chem.* **2006**, *118*, 4664–4673; *Angew. Chem. Int. Ed.* **2006**, *45*, 4552–4560; b) A. K. Mapp, *Org. Biomol. Chem.* **2003**, *1*, 2217; c) J. E. Darnell, Jr., *Nat. Rev. Cancer* **2002**, *2*, 740–749.
- [4] J. M. Mitchell, J. T. Shaw, *Angew. Chem.* **2006**, *118*, 1754–1758; *Angew. Chem. Int. Ed.* **2006**, *45*, 1722–1726; ; D. S. Tan, *Nat. Chem. Biol.* **2005**, *1*, 74–84.
- [5] R. Morgan, *Trends Genet.* **2006**, *22*, 67–69.
- [6] a) I. G. Maroulakou, D. D. Spyropoulos, *Anticancer Res.* **2003**, *23*, 2101–2110; b) D. G. Grier, A. Thompson, A. Kwasniewska, G. J. McGonigle, H. L. Halliday, T. R. Lappin, *J. Pathol.* **2005**, *205*, 154–171.
- [7] C. E. Masse, P. Y. Ng, Y. Fukase, M. Sanchez-Rosello, J. T. Shaw, *J. Comb. Chem.* **2006**, *8*, 293–296.
- [8] P. Y. Ng, C. E. Masse, J. T. Shaw, *Org. Lett.* **2006**, *8*, 3999–4002.
- [9] a) M. Cushman, J. Gentry, F. W. Dekow, *J. Org. Chem.* **1977**, *42*, 1111–1116; b) M. Cushman, E. J. Madaj, *J. Org. Chem.* **1987**, *52*, 907–915.
- [10] a) M. Cushman, L. Cheng, *J. Org. Chem.* **1978**, *43*, 286–288; b) Y. P. Gupta, *J. Am. Chem. Soc.* **1983**, *105*, 2873–2879; c) M. Cushman, M. Jayaraman, J. A. Vroman, A. K. Fukunaga, B. M. Fox, G. Kohlhausen, D. Strumberg, Y. Pommier, *J. Med. Chem.* **2000**, *43*, 3688–3698.
- [11] a) M. C. Griffith, C. T. Dooley, R. A. Houghten, J. S. Kiely, *Mol. Diversity Comb. Chem.: Libr. Drug Discovery, Conf.* **1996**, pp. 50–57; b) M. Lebl, V. Krchnak, G. Ibrahim, J. Pires, C. Burger, Y. Ni, Y. Chen, D. Podue, P. Mudra, V. Pokorny, P. Poncar, K. Zenisek, *Synthesis* **1999**, 1971–1978; c) Y. Ni, V. Krchnak, M. Lebl, *Mol. Diversity* **2000**, *5*, 153–161.
- [12] This high-throughput screen was conducted at the NCI's Initiative for Chemical Genetics (ICG) screening center at the Broad Institute of Harvard and MIT. The data has been deposited in ChemBank (<http://chembank.broad.harvard.edu/>), a freely available resource on the WWW.
- [13] A. K. Franz, P. D. Dreyfuss, S. L. Schreiber, *J. Am. Chem. Soc.* **2007**, *129*, 1020–1021.

- [14] V. Rishi, T. Potter, J. Laudeman, R. Reinhart, T. Silvers, M. Selby, T. Stevenson, P. Krosky, A. G. Stephen, A. Acharya, J. Moll, W. J. Oh, D. Scudiero, R. H. Shoemaker, C. Vinson, *Anal. Biochem.* **2005**, *340*, 259–271.
- [15] The details of the screen are included in the Supporting Information. The high-throughput screen included control experiments examining the changes in fluorescence polarization (FP) when DNA alone, that is, in the absence of HOXA13 binding domain, was treated with screening compounds. In the initial screen, no significant change in FP was observed when DNA alone was treated with **30** or **31**.
- [16] a) H. S. Stadler, K. M. Higgins, M. R. Capecchi, *Development* **2001**, *128*, 4177–4188; b) E. A. Morgan, S. B. Nguyen, V. Scott, H. S. Stadler, *Development* **2003**, *130*, 3095–3109; c) W. Cheng, J. Liu, H. Yoshida, D. Rosen, H. Naora, *Nat. Med.* **2005**, *11*, 531–537.
- [17] W. M. Knosp, V. Scott, H. P. Bächinger, H. S. Stadler, *Development* **2004**, *131*, 4581–4592.
- [18] J. B. Le Pecq, D. Nguyen, C. Gosse, C. Paoletti, *Proc. Natl. Acad. Sci. USA* **1974**, *71*, 5078–5082.
- [19] Screening samples of **30** and **31** were found to be greater than 85 % pure (liquid chromatography–MS) and a sample of **31** was further purified by HPLC for IC₅₀ determination.
- [20] For an early example of a compound from an unbiased combinatorial library that disrupts protein–DNA binding, see S. Y. Stevens, B. A. Bunin, M. J. Plunkett, P. C. Swanson, J. A. Ellman, G. D. Glick, *J. Am. Chem. Soc.* **1996**, *118*, 10650–10651.
- [21] For examples of compounds that disrupt protein–DNA binding discovered by using NMR spectroscopy, see a) P. J. Hajduk, J. Dinges, G. F. Miknis, M. Merlock, T. Middleton, D. J. Kempf, D. A. Egan, K. A. Walter, T. S. Robins, S. B. Shuker, T. F. Holzman, S. W. Fesik, *J. Med. Chem.* **1997**, *40*, 3144–3150; b) J. R. Huth, L. Yu, I. Collins, J. Mack, R. Mendoza, B. Isaac, D. T. Braddock, S. W. Muchmore, K. M. Comess, S. W. Fesik, G. M. Clore, D. Levens, P. J. Hajduk, *J. Med. Chem.* **2004**, *47*, 4851–4857.
- [22] For synthetic polyamides that disrupt or induce transcription-factor binding by targeting DNA, see a) N. R. Wurtz, J. L. Pomerantz, D. Baltimore, P. B. Dervan, *Biochemistry* **2002**, *41*, 7604–7609; b) H.-D. Arndt, K. E. Hauschild, D. P. Sullivan, K. Lake, P. B. Dervan, A. Z. Ansari, *J. Am. Chem. Soc.* **2003**, *125*, 13322–13323; c) D. H. Nguyen-Hackley, E. Ramm, C. M. Taylor, J. K. Joung, P. B. Dervan, C. O. Pabo, *Biochemistry* **2004**, *43*, 3880–3890; d) K. E. Hauschild, R. E. Metzler, H.-D. Arndt, R. Moretti, M. Raffaele, P. B. Dervan, A. Z. Ansari, *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 5008–5013; e) C. L. Warren, N. C. S. Kratochvil, K. E. Hauschild, S. Foister, M. L. Brezinski, P. B. Dervan, G. N. Phillips, Jr., A. Z. Ansari, *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 867–872.